Contact Information: Media Contact: Jackie Ferreira 925.557.4488
Carl Zeiss Meditec Seeks Protection of Proprietary Information
| Source: Carl Zeiss Meditec, Inc.
DUBLIN, CA--(Marketwire - June 18, 2007) - Carl Zeiss Meditec, Inc. (CZMI) has announced
the filing of a lawsuit on June 7, 2007 in the state of Massachusetts
against a former senior CZMI sales executive who is now employed by CZMI's
direct competitor, Optovue, Inc. ("Optovue"). The suit alleges that the
executive, while employed by CZMI, transmitted confidential and proprietary
CZMI information to Optovue, and that he engaged in a variety of prohibited
actions during and subsequent to his CZMI employment. The lawsuit requests
that he be prohibited from engaging in such conduct, be ordered to return
and make no use of CZMI's confidential and proprietary information and
seeks appropriate remedies and awards.
In apparent response to CZMI's filing, Optovue commenced litigation against
CZMI on June 11, 2007 in the federal court in the Northern District of
California. This filing alleges, among other things, that there is a
controversy between Optovue and CZMI regarding whether Optovue engaged in
certain acts of unfair competition, and claims that Optovue did not engage
in such conduct. CZMI intends to respond to that litigation by vigorously
defending against Optovue's claims, and by alleging any appropriate
affirmative claims for unfair competition and otherwise.
While CZMI welcomes fair competition in the marketplace, CZMI will
vigorously protect its confidential, proprietary and trade secret
information, and will take all necessary and appropriate action to enforce
and defend its rights.
"We take the issues CZM has raised in the Massachusetts case as
particularly troublesome since it involves a former senior employee who
occupied a position of trust at CZMI, and who had access to highly
sensitive and proprietary information," said Jim Taylor, president and CEO
of CZMI. "We see Optovue's action to file its own lawsuit as an indication
of the seriousness of CZMI's claims, and welcome, within the structured
process of the legal system, the opportunity to fully pursue the facts
regarding these matters."
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading
medical technology companies. This market position is based on over 160
years of experience in optical innovation. The company has two primary
areas of activity. In the field of ophthalmology, Carl Zeiss Meditec offers
integrated solutions for treating the four main eye diseases: vision
defects (refraction), cataracts, glaucoma and retinal disorders. Product
innovations range from basic systems such as slit lamps and fundus cameras
to standard setting diagnostic systems such as the Humphrey® Field
Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical
microscopes and innovative treatment systems in refractive laser surgery.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's
leading provider of surgical microscopes and microsurgical visualization
solutions for a very broad range of applications, such as tumour and
vascular surgery in the head region and/or spinal surgery. The most recent
example of our innovative performance in the area of microsurgery is the
OPMI Pentero® visualization system, which allows efficient and ergonomic
patient treatment.
Carl Zeiss Meditec's medical technology portfolio is rounded off by
visualization systems for doctors in private practice and promising future
technologies such as intraoperative radiation therapy, which allows the
targeted treatment of breast cancer and brain cancer directly during
surgery.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec
Vertriebsgesellschaf mbH), the USA (Carl Zeiss Meditec, Inc., Dublin,
California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl
Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle,
and Carl Zeiss Meditec France SAS, Le Pecq).
Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss, one of the world's leading
international groups engaged in the optical and opto-electronics industry.
For more information, visit www.meditec.zeiss.com/usa.